Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confir...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Cancer J
Main Authors: Jones, J R, Cairns, D A, Gregory, W M, Collett, C, Pawlyn, C, Sigsworth, R, Striha, A, Henderson, R, Kaiser, M F, Jenner, M, Cook, G, Russell, N H, Williams, C, Pratt, G, Kishore, B, Lindsay, J, Drayson, M T, Davies, F E, Boyd, K D, Owen, R G, Jackson, G H, Morgan, G J
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2016
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5223149/
https://ncbi.nlm.nih.gov/pubmed/27935580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.114
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker